Dexcom G7 Stolen-Sensor Market Withdrawal Remains Active — Two CGM Lots Pulled From Unauthorized Supply Chain, One With Infection Risk

Sensors destined for destruction were intercepted by a third-party thief and sold through Pharmsource LLC. One lot carries inadequate sterilization; the other may deliver no glucose readings at all.

Dexcom initiated a market withdrawal on May 26, 2026, after discovering that two lots of its G7 continuous glucose monitor sensors — units already condemned to industrial destruction — had been stolen and funneled into the commercial supply chain. The action remains active through June 2026, and the Food and Drug Administration has posted the alert under its recalls, market withdrawals, and safety alerts framework.

A market withdrawal differs from a Class I or Class II recall in a precise regulatory sense: the product was not distributed through Dexcom’s own authorized channels, and the company is acting voluntarily to remove it rather than responding to a formal FDA-mandated recall order. That distinction does not diminish the clinical stakes.

The two affected lots carry distinct hazard profiles. Lot 1725204004 was pulled because the sensors were never properly sterilized before being scrapped; patients who insert them face an elevated risk of skin or subcutaneous infection at the application site. Lot 1725069002 was condemned internally for an elevated testing-failure rate; sensors from this lot risk delivering no glucose readings whatsoever — a silent failure with no alarm, no alert, and no data.

For insulin-dependent patients, particularly those with type 1 diabetes, a silent CGM failure is not a minor inconvenience. Without real-time glucose data, hypoglycemia can go undetected for hours. The G7 is marketed specifically to replace fingerstick monitoring during routine daily management, meaning users may have no secondary alerting system in place.

Dexcom traced the stolen product to Pharmsource LLC, an unauthorized distributor that supplies a network of independent pharmacies and durable medical equipment distributors across the United States. Pharmsource is not an approved Dexcom distribution partner. The company has not disclosed how many sensors from the two lots reached patients.

As of the announcement date, Dexcom reported no severe adverse events associated with either lot. The company has established a verification portal for patients and providers to check lot numbers, and it is offering free replacements to anyone who received an affected sensor.

Patients and pharmacists can verify devices by checking the lot number printed on the G7 sensor packaging. Anyone holding either lot should stop use immediately and contact Dexcom customer support.

Trace · every claim, sourced

Reported and written by Dr. Nadia Haq, Devices & Diagnostics Desk, then each load-bearing claim was bound to the primary source it rests on and checked out-of-band against that source before publication. The full mapping is below — nothing here is taken on faith.

Dexcom initiated a market withdrawal on May 26, 2026, after discovering two G7 CGM lots stolen from destruction supply chain and sold via Pharmsource LLC

regulator Dexcom Uncovers Theft of Scrapped Product, Notifies Potentially Impacted Users — FDA Safety Alert fda-dexcom-g7-stolen-market-withdrawal-may2026

Lot 1725204004: inadequate sterilization, elevated risk of skin or subcutaneous infection at the application site

regulator Dexcom Uncovers Theft of Scrapped Product, Notifies Potentially Impacted Users — FDA Safety Alert fda-dexcom-g7-stolen-market-withdrawal-may2026

Lot 1725069002: elevated internal testing-failure rate; sensors risk delivering no glucose readings

regulator Dexcom Uncovers Theft of Scrapped Product, Notifies Potentially Impacted Users — FDA Safety Alert fda-dexcom-g7-stolen-market-withdrawal-may2026

No severe adverse events reported as of announcement date

regulator Dexcom Uncovers Theft of Scrapped Product, Notifies Potentially Impacted Users — FDA Safety Alert fda-dexcom-g7-stolen-market-withdrawal-may2026

After publication, a separate AI panel re-verifies every edition against these same sources. The running claim-confirmation rate and every correction are public on the accuracy ledger.